THE CONSORTIUM DEVELOPING A UNIQUE HUMAN RIFT VALLEY FEVER VACCINE
We are a consortium of six partners with a single goal: the development and evaluation of a vaccine for the prevention of Rift Valley fever in humans. The project is named "LARISSA", acronym for Live Attenuated Rift Valley Fever Vaccine for Single Shot Application.
The project is financed by the Coalition for Epidemic Preparedness Innovations (CEPI), with support from EU Horizon 2020 programme. CEPI aims to accelerate the development of vaccines against emerging infectious diseases and to enable equitable access to these vaccines in the face of outbreaks.
Wageningen Bioveterinary Research
Wageningen Bioveterinary Research (WBVR) is a business unit of Wageningen University Research (WUR) in the Netherlands. WBVR contributes to the prevention, eradication and control of animal infectious diseases and zoonoses in the Netherlands through research, diagnostics and consultancy.
CR2O BV is a full service CRO for public organizations, biotech and pharma industries. CR2O combines strong scientific leadership and operational excellence to conduct innovative national and global clinical trials. CR2O built extensive experience managing and implementing phase I-IV clinical trials.
IDT Biologika GmbH (IDT) was founded in 1921 and has developed into one of the world's leading pharmaceutical and biotech companies with a focus on manufacturing of vaccines. IDT is internationally recognized for its technically sophisticated vaccine development know-how as well as high-quality standards for handling and manufacturing biopharmaceuticals
Research Centre for Emerging Infections and Zoonoses
Research Centre for Emerging Infections and Zoonoses (RIZ) is a ‘One Health’ research centre embedded in the University of Veterinary Medicine Foundation, Hannover (TiHo). RIZ research focuses on the identification and characterization of emerging animal and human viruses, and development of intervention strategies to control their impact.
Centre for Vaccinology
Centre for Vaccinology (CEVAC) consists of the Clinical Trial Unit and the Immunomonitoring Laboratory. These two units are affiliated with Ghent University Hospital (UZGent) and Ghent University (UGent), respectively. Since 1986, CEVAC-CTU has conducted more than 250 clinical vaccine trials and CEVAC-LAB has strong expertise in immunomonitoring.
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations launched in Davos in 2017 to develop vaccines to stop future epidemics. CEPI has received multi-year funding from Norway, Germany, Japan, Canada, Australia, and the Bill & Melinda Gates Foundation, and Wellcome. CEPI has also received single-year investments from the Governments of Belgium and the United Kingdom. The European Union provides financial support for relevant projects through their Horizon 2020 programme as well as through the European and Developing Countries Clinical Trials Partnership. CEPI has reached over US$ 750 million of its $1 billion funding target. Since its launch in January 2017, CEPI has announced three calls for proposals. The first call was for candidate vaccines against Lassa virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Nipah virus. The second call was for the development of platforms that can be used for rapid vaccine development against unknown pathogens. The third call is for candidate vaccines against Chikungunya and Rift Valley fever viruses.
" With this strategic collaboration, CEPI acknowledges the concept of One Health, by bringing together veterinary and public health experts to fight an emerging virus that affects both animals and humans."
Prof. Jeroen Kortekaas
Project Lead and Molecular Virologist at Wageningen Bioveterinary Research